OptimizeRx (OPRX) AI Stock Analysis

• Market Cap: $124.21M
• Dividend Yield: N/A
• Average Volume (3M): 499.37K
• Price to Earnings (P/E): 44.3
• Beta (1Y): 2.13
• Revenue Growth: 24.19%
• EPS Growth: N/A
• Country: US
• Employees: 128
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.51
• Shares Outstanding: 18,762,203
• 10 Day Avg. Volume: 631,011
• 30 Day Avg. Volume: 499,368
• PEG Ratio: -0.35
• Price to Book (P/B): 1.77
• Price to Sales (P/S): 2.08
• P/FCF Ratio: 12.19
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 1.16
• Enterprise Value/Gross Profit: 1.83
• Enterprise Value/Ebitda: 7.75
• 1Y Price Target: $13.92
• Price Target Upside: 110.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 0.97
• Revenue Forecast (FY): $121.63M

• Rating: 64 Neutral
• Price Target: $6.50 ▼(-1.81% Downside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is driven primarily by improving fundamentals—strong 2025 cash flow and profitability alongside a low-leverage balance sheet. Offsetting this, the stock’s technical setup is weak (below all key moving averages with negative MACD), valuation is relatively expensive (P/E ~44), and management’s 2026 outlook is cautious on revenue with mix-related headwinds despite maintaining healthy EBITDA expectations.

Positive Factors

Strong cash generation

A sustained swing to positive operating and free cash flow (~$18.7M in 2025) materially improves the company's ability to fund operations, invest in product and sales, pay down debt, or execute buybacks without relying on external capital—supporting durable financial flexibility.

Low leverage / conservative balance sheet

Very low debt-to-equity and recent principal paydowns reduce refinancing and solvency risk, giving management room to prioritize profitable growth, opportunistic buybacks or M&A. A conservative capital structure increases resilience across business cycles and supports long-term strategy execution.

High retention and productivity

A 116% net revenue retention rate plus meaningful revenue-per-employee gains signal strong account stickiness and scalable economics. High retention implies recurring revenue durability, reducing customer acquisition pressure and supporting margin expansion as platform adoption deepens.

Negative Factors

Managed-services revenue not repeatable

Dependence on one-off managed-services revenue that is unlikely to recur reduces topline durability; losing ~$9M of higher-margin or variable services revenue forces reliance on core subscription/campaign business and makes multi-year revenue predictability weaker.

Gross margin normalization risk

A one-off spike to ~74.8% gross margin driven by mix implies future margin pressure as favorable channels or specialty messaging normalize to mid-60% range. Sustained margin compression would limit operating leverage and constrain long-term profitability improvements.

Contract visibility and client conservatism

Shorter contracts, MFN-driven client caution and contracted revenue tracking ~15–20% below normal reduce multi-quarter visibility and increase revenue volatility. This makes planning, sales cadence and investment timing harder, elevating execution risk during industry spending shifts.

OptimizeRx Business Overview & Revenue Model

Company Description

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.

How the Company Makes Money

OptimizeRx primarily makes money by providing commercial engagement and support services to pharmaceutical and life sciences customers, generally monetized through contracts tied to campaigns, programs, or subscriptions that place brand and patient-support messages into clinical and consumer digital channels. Key revenue streams typically include: (1) point-of-care and provider-facing messaging programs, where pharmaceutical brands pay to deliver targeted content and offers to clinicians within EHR and other clinical workflow systems; (2) patient engagement and access/affordability solutions, where manufacturers pay to distribute co-pay/savings offers, patient support resources, and adherence-related communications through digital channels; and (3) enterprise and platform-based arrangements, where customers contract for broader omnichannel capabilities and measurement/optimization services across multiple brands or programs. Revenue is supported by the company’s distribution network and integrations that enable access to clinicians and patients at scale; specific partnership counterparties and contract terms are not available in this prompt and are therefore null.

OptimizeRx Financial Statement Overview

Summary

Financial profile improved meaningfully in 2025 with a swing to positive net income, strong free cash flow (~$18.7M) that aligns with earnings quality, and a de-levered balance sheet (debt-to-equity ~0.04). The main offsets are the 2025 revenue decline (-7%) and historical volatility in earnings/cash flow, which keep the score below top-tier.

Income Statement

Revenue has grown strongly over the long run (2020–2024), but 2025 revenue declined (-7%), signaling a near-term slowdown. Profitability has improved materially: the company swung from sizable losses in 2022–2024 to positive net income in 2025 ($5.1M) with solid gross margins (~67%). However, net margin remains modest (~4.7%) and results have been volatile across years, which tempers the score.

Balance Sheet

The balance sheet looks conservatively positioned with low leverage in 2025 (debt-to-equity ~0.04) and a sizable equity base ($128.3M) relative to assets ($176.9M). Debt has been reduced sharply versus 2023–2024, improving financial flexibility. Return on equity is positive in 2025 (~4%), though still not particularly high, reflecting that profitability is improving but not yet consistently strong.

Cash Flow

Cash generation strengthened significantly in 2025, with operating cash flow of $18.7M and free cash flow of $18.7M, up sharply year over year (free cash flow growth ~60%). Free cash flow is closely aligned with reported earnings in 2025, supporting earnings quality. The main weakness is historical variability, including negative operating/free cash flow in 2020 and 2023, indicating cash conversion has not been consistently stable through cycles.

Breakdown	Dec 2025	Dec 2024	Mar 2024	Dec 2022	Dec 2021
Income Statement
Total Revenue	109.43M	92.13M	71.52M	62.45M	61.29M
Gross Profit	69.27M	59.38M	42.90M	38.97M	35.64M
EBITDA	16.39M	-8.90M	-21.31M	-9.42M	2.33M
Net Income	5.13M	-20.11M	-17.57M	-11.44M	378.08K
Balance Sheet
Total Assets	176.92M	171.17M	183.37M	134.65M	140.99M
Cash, Cash Equivalents and Short-Term Investments	23.36M	13.38M	13.85M	74.14M	84.68M
Total Debt	26.10M	33.19M	36.82M	234.43K	327.71K
Total Liabilities	48.62M	54.17M	56.82M	8.54M	9.61M
Stockholders Equity	128.29M	117.00M	126.55M	126.11M	131.38M
Cash Flow
Free Cash Flow	18.66M	4.78M	-8.11M	10.41M	240.04K
Operating Cash Flow	18.71M	4.89M	-7.24M	10.65M	726.04K
Investing Cash Flow	68.00K	-450.00K	-25.34M	-58.18M	-486.00K
Financing Cash Flow	-8.80M	-4.91M	28.22M	-18.95M	73.92M

OptimizeRx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.62
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPRX, the sentiment is Negative. The current price of 6.62 is below the 20-day moving average (MA) of 7.29, below the 50-day MA of 9.78, and below the 200-day MA of 14.25, indicating a bearish trend. The MACD of -0.95 indicates Negative momentum. The RSI at 35.60 is Neutral, neither overbought nor oversold. The STOCH value of 40.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OPRX.

OptimizeRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPOK	73 Outperform	$237.98M	17.11	10.63%	9.67%	1.47%	11.33%
HSTM	69 Neutral	$614.43M	37.76	5.87%	0.52%	3.68%	5.62%
OPRX	64 Neutral	$124.21M	44.33	4.22%	―	24.19%	―
TBRG	57 Neutral	$236.39M	13.03	3.23%	―	3.75%	―
OMCL	54 Neutral	$1.59B	1,014.72	0.17%	―	10.67%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SOPH	48 Neutral	$358.34M	-3.99	-116.98%	―	13.66%	-2.65%

OptimizeRx Corporate Events

OptimizeRx Authorizes $10 Million Share Repurchase Program

On March 2, 2026, OptimizeRx amended its financing agreement to extend the maturity date by two years to October 11, 2029, lengthen the period during which a 1% premium applies, and secure flexibility to repurchase up to $10 million of stock by March 15, 2027. On March 5, 2026, the board formally authorized a share buyback of up to $10 million, to be funded from cash and executed via open-market or private transactions, underscoring confidence in the company’s balance sheet after a strong 2025, improved profitability and incremental term-loan paydown.

For the fourth quarter of 2025, OptimizeRx reported essentially flat revenue at $32.2 million but expanded gross profit and delivered record GAAP net income of $5.0 million and adjusted EBITDA of $12.0 million. For full-year 2025, revenue grew 19% to $109.4 million, GAAP net income swung to a $5.1 million profit from a $20.1 million loss, adjusted EBITDA more than doubled to $24.3 million and operating cash flow rose to $18.7 million, positioning the company as a Rule of 40 performer despite management flagging near-term demand headwinds from life sciences spending caution.

Key operating metrics for 2025 showed net revenue retention of 116%, lower revenue concentration from the top 20 pharma manufacturers at 52% of total revenue and higher revenue per employee, indicating a broader customer base and efficiency gains. Management updated 2026 guidance to revenue of $109 million to $114 million and adjusted EBITDA of $21 million to $25 million, suggesting modest growth and sustained profitability as OptimizeRx seeks to maintain Rule of 40 status amid market volatility and evolving pharma marketing dynamics.

The most recent analyst rating on (OPRX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on OptimizeRx stock, see the OPRX Stock Forecast page.